Repligen Corporation announced it has entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligand, NGL-Impact A, which will be commercialized by Purolite Life Sciences using their novel Praesto( agarose jetting base bead technology. Repligen is a longtime market leader in Protein A, with two facilities that produce the majority of the global Protein A ligand demand to biopharmaceutical customers worldwide.NGL-Impact A was developed as part of Repligen's collaboration with Navigo Proteins GmbH. This new ligand has outstanding performance attributes when immobilized on jetted agarose bead technology, with ultra-high binding capacities and excellent alkaline stability. These attributes are important in providing improved monoclonal antibody capture to handle increased upstream product titres, and in allowing higher concentrations of sodium hydroxide for sanitization of resins. Purolite Life Sciences's jetting technology is a new patented method that produces agarose beads with a uniform particle size distribution to drive higher capacity and increase pressure flow properties.
